GRIA2 and Parkinson disease: Interestingly, miR-181a negatively controls parkin [135], which is a key factor in PD pathomechanisms [111] and, as a consequence, directly impairs the expression of the glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) [136].